Cell and Gene Therapy Drug Delivery Devices Market - Know the Untapped Revenue Growth Opportunities

Cell and Gene Therapy Drug Delivery Devices Market worth US$ 422.83 Thousands by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cell and Gene Therapy Drug Delivery Devices Market- by Products (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Pre-Filled Syringe, and Infusion Bags), Commercialized Drugs (Luxturna, Kymriah, Provenge, Zolgensma, Yescarta, and Strimvelis), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get Free Sample Copy of Report : https://www.insightaceanalytic.com/request-sample/1025
The global market for cell and gene therapy drug delivery devices is estimated to be worth US$ 116.29 thousand in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 15.96% between 2022 and 2030. This information is based on research conducted by InsightAce Analytic.
To provide a highly customized treatment, cells, proteins, or genetic material (DNA) from the donor are taken out and altered in cell and gene therapy. Gene and cell therapies may have longer-lasting effects than conventional medications. One of the critical medications in the cell and gene therapy industries is CAR-T cell-based therapy, which encompasses both cell treatment and gene therapy. Cell and gene therapy drug delivery is a rapidly evolving field whose full potential has recently come to light. There's a good possibility that these procedures will have an effect. Furthermore, there has been a rapid improvement worldwide in the overall efficacy and capacity to kill cancer cells without damaging healthy tissues.
The primary drivers of growth in this market are:
• The increasing prevalence of chronic illnesses and cancer
• The growing funding for gene and cell therapies
• The rising need for novel treatments for uncommon diseases
• The increase in biopharmaceutical R&D spending
• The number of FDA-approved clinical trials and cell and gene therapies
Globally increasing geriatric population, increasing cancer incidence, and genetic anomalies are expected to drive a significant increase in the requirement for cell and gene therapy pharmaceutical delivery devices. Businesses are also investing a large sum of money in developing related medication delivery technologies and gene and cell therapies. The market for drug delivery systems for gene and cell therapies is expected to be driven by the recent rise in the number of chronic and hereditary disorders being researched in clinical trials. The market is expected to increase significantly because of the many growth opportunities within the industry, including drug approvals and a strong pipeline of cell and gene therapies. However, as the terrible disease started to spread, industry players focused more on finding solutions to the pandemic's problems, which prevented market growth. The primary factor that may restrain the expansion of the global market for drug delivery devices used in gene and cell therapy in the upcoming years is the high cost of manufacturing these medications.
Over the projected years, North America is expected to contribute significantly to the market for drug-delivery devices for cell and gene therapy. The expansion of alliances amongst numerous small- and medium-sized enterprises and conglomerates has made it possible to develop premium, cost-effective medications. The increasing prevalence of neurodegenerative diseases and the growing need for efficient treatments for gene disorders that can be discovered through research, diagnostics, and synthetic biology were significant factors that also contributed significantly to the regional market's expansion. Furthermore, the demand for cell and gene therapy drug delivery devices in the Asia Pacific region is anticipated to grow considerably over the projected period due to significant investments made by the pharmaceutical and biotechnology industries, improved healthcare facilities, higher per capita income, early access to approved medications, and the region's concentration of state-of-the-art research facilities and laboratories.
Requesting a proposal or ToC:
Amgen Inc., Becton, Bausch & Lomb Incorporated., Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.), Vericel Corporation, Bluebird bio, Inc., Dendreon Pharmaceuticals LLC., Dickinson and Company, Helixmith Co., Ltd (ViroMed Co., Ltd), Kite Pharma, Inc., Human Stem Cells Institute, Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Renova Therapeutics, Kolon TissueGene, Inc., Spark Therapeutics, Inc., uniQure N.V., and a list of other notable players are among the major market players operating in the Cell and Gene Therapy Drug Delivery Devices market.

Recent collaborations and agreements in the market:
• In 2020, Lonza (Switzerland) and IsoPlexis (US) teamed up to create the next generation of precision cell therapy manufacturing.
• In 2020, Danaher acquired General Electric Company's Life Sciences division's Biopharma business (US). Danaher acquired General Electric Company's Life Sciences division's Biopharma business. Cytiva, a standalone operational company within Danaher's Life Sciences segment, was formed as a result of the acquisition.
• In 2019, Thermo Fisher Scientific spent USD 24 million in its Inchinnan (Scotland) location to increase its worldwide bioproduction capabilities by adding large-volume liquid manufacturing capacity for cell culture medium.
Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1025
Market Segments
Global Cell and Gene Therapy Drug Delivery Devices Market, by Products, 2022-2030 (Value US$ Th)
• Subretinal Injection Cannula
• Extension Tube
• Intravenous Catheter
• Sterile Insulin Syringe
• Pre-Filled Syringe
• Infusion Bags
Global Cell and Gene Therapy Drug Delivery Devices Market, by Commercialized Drugs, 2022-2030 (Value US$ Th)
• Luxturna
• Kymriah
• Provenge
• Zolgensma
• Yescarta
• Strimvelis
Global Cell and Gene Therapy Drug Delivery Devices Market, by Region, 2022-2030 (Value US$ Th)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Cell and Gene Therapy Drug Delivery Devices Market, by Country, 2022-2030 (Value US$ Th)
• U.S.
• Canada
Europe Cell and Gene Therapy Drug Delivery Devices Market, by Country, 2022-2030 (Value US$ Th)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Cell and Gene Therapy Drug Delivery Devices Market, by Country, 2022-2030 (Value US$ Th)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Cell and Gene Therapy Drug Delivery Devices Market, by Country, 2022-2030 (Value US$ Th)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Cell and Gene Therapy Drug Delivery Devices Market, by Country, 2022-2030 (Value US$ Th)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global Cell and Gene Therapy Drug Delivery Devices market
 To receive an industry overview and future trends of the Cell and Gene Therapy Drug Delivery Devices market
 To analyze the Cell and Gene Therapy Drug Delivery Devices market drivers and challenges
 To get information on the Cell and Gene Therapy Drug Delivery Devices market value (US$Th) forecast to 2030
 Significant investments, mergers & acquisitions in the Cell and Gene Therapy Drug Delivery Devices market industry
For More Customization @ https://www.insightaceanalytic.com/customisation/1025

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.